Welcome to C2I's newest tenants: SynerK, Inc.

We would like to extend a warm welcome to the newest members of the C2I family.

SynerK, Inc. is a biotechnology company engaged in the development of life changing treatment in the areas of cancer, inflammatory and rare diseases. SynerK utilizes antisense technology to specifically silence genes that are responsible for various diseases.